LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways   Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progres

Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024. The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Third Quarter 2024 Financial Results The webcast will also be avai

Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET. A live audio webcast of the chat will be available on the Events page of the Compass website and will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives o

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetingsH. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:30 am ET on September 10, 2024, and host investor meetingsCantor Global Healthcare Conference: fireside chat at 2:30 pm ET on September 17, 2024, and host investor meetings A li

LONDON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Canaccord Genuity 44th Annual Growth Conference: presentation at 4:30pm ET on August 13, 2024 and host investor meetings. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of this webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com. About Compass Pathways   Compass Pathways plc (

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2024 and an update on recent business progress. "As we continue to

LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, and provide an update on recent business developments, on August 1, 2024. The management team will host a conference call at 8:00 am ET (1:00 pm UK) on August 1, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: Second Quarter 2024 Financial Res

New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024. The company will also participate in a panel discussion titled "Commercialization of Novel Compounds in Psychiatry" at 12:00pm ET on June 27, 2024. A live audio webcast of these events will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following su

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

4 - COMPASS Pathways plc (0001816590) (Issuer)

SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

SC 13G - COMPASS Pathways plc (0001816590) (Subject)

SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

SC 13G - COMPASS Pathways plc (0001816590) (Subject)

SC 13G - COMPASS Pathways plc (0001816590) (Subject)

SC 13G - COMPASS Pathways plc (0001816590) (Subject)

SC 13G - COMPASS Pathways plc (0001816590) (Subject)

SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

8-K - COMPASS Pathways plc (0001816590) (Filer)

10-Q - COMPASS Pathways plc (0001816590) (Filer)

424B5 - COMPASS Pathways plc (0001816590) (Filer)

EFFECT - COMPASS Pathways plc (0001816590) (Filer)

S-3 - COMPASS Pathways plc (0001816590) (Filer)

8-K - COMPASS Pathways plc (0001816590) (Filer)

10-Q - COMPASS Pathways plc (0001816590) (Filer)

F-6EF - COMPASS Pathways plc (0001816590) (Subject)

8-K - COMPASS Pathways plc (0001816590) (Filer)

10-Q - COMPASS Pathways plc (0001816590) (Filer)

RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

Morgan Stanley initiated coverage of COMPASS Pathways with a rating of Overweight and set a new price target of $30.00

Deutsche Bank initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $16.00

Berenberg resumed coverage of COMPASS Pathways with a rating of Buy and set a new price target of $33.00

Loop Capital initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $34.00

HC Wainwright & Co. reiterated coverage of Compass Pathways with a rating of Buy and set a new price target of $120.00 from $100.00 previously

Oppenheimer initiated coverage of Compass Pathways with a rating of Outperform and set a new price target of $50.00

Citigroup initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $67.00

Maxim Group initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $70.00

BTIG initiated coverage of Compass Pathways with a rating of Buy and set a new price target of $63.00

New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases. "Daphne is an ideal match for the COMPASS Pathways Board of Directors as we progress our phase 3 COMP360 psilocybin program in treatment-resistant depression and our phase

Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December 2021        COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Matthew Owens as General Counsel and Chief Legal Officer. Mr Owens will join COMPASS on 1 February 2022. The company also announced that Lars Wilde, President, Chief Business Officer and Co-founder, will be moving into a senior advisory role with COMPASS from 1 January 2022. Matthew O

London, UK - 3 December 2021 COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year. Michael Falvey is highly experienced in delivering financial and operational excellence in public and private growth companies. He joins COMPASS most recently from Karyopharm Therapeutics, where he led the financial strategy and prepared the financial infrastructure to support commercial operations as the

      London, UK – 21 July 2021         COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS's Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health innovation. Danielle Schlosser joins COMPASS from Verily Life Sciences, a sister company to Google, where she was Behavioural Health Lead, overseeing the launch of several products including digital measurement capabilities and

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors London, UK – 1 April 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has appointed Wayne J Riley MD to its Board of Directors. Dr Riley is President of the State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. A primary care physician and an academic, he has more than 25 years of experience encompassing clinical and academic medicine, rese

NEW YORK--(BUSINESS WIRE)--Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm’s investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector. The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker

ATLANTA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadruple. Psychedelic stocks are in a fast moving sector characterized by companies many analysts would consider speculative and overpriced; however, it is our opinion many psychedelic companies will continue to defy the rules of investing and bulldoze their way to higher prices in 2021. New leaders may emerge, but the reason for this increased interest in psychedelics is improved mental heal

RBC Capital analyst Leonid Timashev initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Outperform rating and announces Price Target of $23.

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"

Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from Benzinga Pro. Lands’ End shares dipped 9.3% to $12.60 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at thr

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD). The Details: MindMed and other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:ATAI) and COMPASS Pathways Plc (NASDAQ:CMPS), are down after an FDA panel rejected the use of MDMA-assisted therapy for PTSD on Tuesday. The FDA panel voted 9 to 2 on whether the MDMA-assisted therapy was effective and 10 to 1 on whether the proposed treatment's benefits outweighed its risks. Members of the panel expressed concerns about the designs of the two studies submitte

U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday. Shares of DouYu International Holdings Limited (NASDAQ:DOYU) fell in today's pre-market trading following first-quarter results. DouYu International reported a fiscal first-quarter 2024 revenue decline of 29.9% to $144 million year-on-year, missing the analyst consensus estimate of $184 million. The Chinese game-centric live streaming platform's adjusted earnings per ADS loss of 37 cents compared to $1.10 Y/Y, according to data from Benzinga Pro. DouYu International shares fell 4.2% to $9.70 in pre-market trading. Here are some big stocks recording losses in today's pre-market

Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) stock moved upwards by 29.04% to $2.71. The company's market cap stands at $117.6 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares increased by 21.69% to $2.3. The market value of their outstanding shares is at $89.7 million. Heart Test Laboratories (NASDAQ:HSCS) stock moved upwards by 12.87% to $5.81. The company's market cap stands at $3.8 million. I-MAB (NASDAQ:IMAB) shares increased by 12.23% to $2.11. The company's market cap stands at $170.6 million. Agenus (NASDAQ:AGEN) stock

Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%. Quarterly sales came in at $322.7 million which beat the analyst consensus estimate of $306.121 million by 5.42% and represents a 18.29% decrease in sales from the same period last year, according to data from Benzinga Pro. Stitch Fix shares jumped 18% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 7